La Montagna Manuela, Ginn Lucy, Garofalo Michela
Transcriptional Networks in Lung Cancer Group, Cancer Research UK Manchester Institute, University of Manchester, Alderley Park, Manchester, SK10 4TG, UK.
Cancer Research UK Lung Cancer Centre of Excellence at Manchester and University College London, London, UK.
Cancer Gene Ther. 2021 Apr;28(3-4):175-187. doi: 10.1038/s41417-020-00214-3. Epub 2020 Aug 25.
Non-small-cell lung cancer (NSCLC) is the most prevalent form of lung cancer and has a poor five-year survival rate of 15%. Chemotherapy and targeted therapies have significantly improved patients' prognosis. Nevertheless, after a successful initial response, some patients relapse when cancer cells become resistant to drug treatments, representing an important clinical limitation. Therefore, investigating the mechanisms of drug resistance is of significant importance. Recently, considerable attention has been given to long non-coding RNAs (lncRNAs), a heterogeneous class of regulatory molecules that play essential roles in tumorigenesis by modulating genes and signalling pathways involved in cell growth, metastasis and drug response. In this article, we review recent research findings on the role of lncRNAs in drug resistance in NSCLC, highlighting their mechanisms of action.
非小细胞肺癌（NSCLC）是最常见的肺癌形式，其五年生存率低至15%。化疗和靶向治疗显著改善了患者的预后。然而，在初始治疗取得成功后，一些患者会出现复发，因为癌细胞对药物治疗产生了耐药性，这是一个重要的临床局限性。因此，研究耐药机制具有重要意义。最近，长链非编码RNA（lncRNAs）受到了广泛关注，这是一类异质性的调节分子，通过调节参与细胞生长、转移和药物反应的基因及信号通路，在肿瘤发生过程中发挥着重要作用。在本文中，我们综述了lncRNAs在NSCLC耐药中作用的最新研究发现，重点介绍了它们的作用机制。
